. Imalumab is Baxalta's lead candidate anti-oxMIF antibody which is currently tested in a phase I clinical trial (ClinicalTrials.gov identifier: NCT01765790).Methods: Biodistribution of anti-oxMIF antibodies was assessed (i) in a murine genetic model of pancreatic cancer and (ii) in biopsies...
Results Of the cohort of 75,158 patients with schizophrenia-spectrum or bipolar disorder, 16,387 were assigned to the validation sample and the remainder to the derivation sample. Baseline characteristics of the derivation sample are shown in Table 1. In the derivation sample, 494 individuals (0.8...
The first generation anti-oxMIF antibody imalumab (synonyms: BAX69, BaxB01) demonstrated promising results in a phase I clinical trial with an acceptable safety profile [19]. However, imalumab showed an unusually short half-life in patients, increased aggregation propensity, and an unfavorable ph...
TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT01686802 . 2017 Canadian Medical Association or its licensors.doi:10.1503/cmaj.170017Poonai, NaveenDatoo, NatashaAli, SaminaCashin, MeganDrendel...